RSS
28 Dec 2021

Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease

Author: admintech | Filed under: Press Release

CRANBURY, N.J., Dec. 28, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of…

This entry was posted on Tuesday, December 28th, 2021 at 7:41 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»